Edition:
United Kingdom

Immutep Ltd (IMMP.OQ)

IMMP.OQ on NASDAQ Stock Exchange Global Market

3.01USD
21 Sep 2018
Change (% chg)

$-0.04 (-1.31%)
Prev Close
$3.05
Open
$3.10
Day's High
$3.18
Day's Low
$2.96
Volume
25,862
Avg. Vol
16,579
52-wk High
$3.34
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Immutep Ltd Enters Into Clinical Trial Collaboration With Merck & Co
Sunday, 11 Mar 2018 

March 12 (Reuters) - Immutep Ltd ::ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK & CO., INC.DEAL TO EVALUATE COMBINATION OF IMMUTEP'S IMMUNOTHERAPY PRODUCT CANDIDATE WITH MSD'S ANTI-PD-1 THERAPY KEYTRUDA IN A NEW CLINICAL TRIAL.  Full Article

Prima Biomed says Lucy Turnbull steps down as chairman​
Thursday, 16 Nov 2017 

Nov 17 (Reuters) - Prima Biomed Ltd ::Russell Howard appointed as chairman​.Lucy Turnbull steps down as chairman​.‍vice-Chairman Albert Wong to step down​.  Full Article

Prima Biomed files for offer and sale of up to 197.35 mln ordinary shares
Thursday, 19 Oct 2017 

Oct 20 (Reuters) - Prima Biomed Ltd :Prima Biomed Ltd files for offer and sale of up to 197.35 million ordinary shares, represented by 1.97 million adss‍​ by selling shareholders - SEC filing.  Full Article

Prima Biomed ‍received approval for intiation of ‘Insight’ clinical trial
Monday, 10 Jul 2017 

July 10 (Reuters) - Prima Biomed Ltd :Received regulatory and ethical approvals for clinical trial investigating IMP321 in new settings, called Insight​.Approval has been received from Paul-Ehrlich-Institut, Federal Institute For Vaccines And Biomedicines For German Federal Ministry Of Health.  Full Article